# EDGAR Filing Document

**Accession Number:** 0001750149
**File Stem:** 9999999995-23-000304
**Filing Date:** 2023-2
**Character Count:** 1298
**Document Hash:** bfbde90156ff3b3c243ad7a752f7d7fc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**9999999995-23-000304.hdr.sgml**: 20230208

**ACCESSION NUMBER**: 9999999995-23-000304

**CONFORMED SUBMISSION TYPE**: EFFECT

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230207

**DATE AS OF CHANGE**: 20230208

**EFFECTIVENESS DATE**: 20230207

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inhibikase Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001750149
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** EFFECT
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-269521
- **FILM NUMBER:** 23596891

**BUSINESS ADDRESS:**
- **STREET 1:** 3350 RIVERWOOD PARKWAY SE, SUITE 1900
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30339
- **BUSINESS PHONE:** 678-392-3419

**MAIL ADDRESS:**
- **STREET 1:** 3350 RIVERWOOD PARKWAY SE, SUITE 1900
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30339

### UNITED STATES
### SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## Notice of Effectiveness

**Date:** February 7, 2023

**Time:** 15:00:00

**Form Type:** S-1

---

**CIK:** 0001750149

**Company Name:** Inhibikase Therapeutics, Inc.

**File Number:** 333-269521